Organon introduces JADA system for postpartum hemorrhage

Makes bid into the Korean market with the company’s new treatment option

New product approval comes nearly 3 years after the company’s establishment in Korea in June 2021

About 20% of mothers experience postpartum hemorrhage... targets the unmet need

Conventional balloon dilation takes 12 to 24 hours...whereas JADA controls the bleeding in a median of 3 minutes

Organon, which emphasizes its focus on women's health after spinning off from MSD, has launched its first product in Korea.

 

The JADA system (JADA), a medical device for the control and treatment of postpartum hemorrhage, is the first product the company released in Korea since Organon officially launched its Korean subsidiary in June 2021.

 

JADA, which can be used for intrauterine negative pressure hemostasis, was recognized as a safe and effective new health technology by the National Evidence-based Healthcare Collaborating Agency (NECA) late last month.

 

For Organon, the approval of JADA is significant because it is the first new product the company has introduced in Korea since the spin-off.

 

Since its launch, the company has been differentiating itself by providing solutions focused on women's health, and the JADA aligns with the company’s purpose.

 

Among Organon's many solutions at the global level, the company chose to first introduce the JADA system to Korea to address the unmet need for postpartum hemorrhage.

 

According to Organon, postpartum hemorrhage is one of the most common birth complications, but can even result in maternal death.

 

According to a national survey conducted from 2009 to 2014, about one-fifth of all mothers experience postpartum hemorrhage.

 

In other words, the introduction of the JADA system has significance because it provides a new treatment option that can quickly and accurately control postpartum hemorrhage, which is of high concern amid the declining birthrate and rising interest in maternal health.

 

"JADA is the first fruit born through Organon's efforts to deliver new treatment options for unmet needs in women's health since its inception," said So Eun Kim, Managing Director of Organon Korea.

 

"We will continue to lead the way in providing various innovative medicines and solutions that address the health challenges that women may face throughout their lifecycles."

Product photo of the JADA system and a schematic diagram of its mechanism of action

JADA is the first new technology introduced in 15 years since the introduction of the intrauterine balloon tamponade and compression suture.

 

While conventional intrauterine balloon tamponade systems achieved hemostasis by applying direct pressure to the lining of the uterus for 12 to 24 hours, JADA creates a negative pressure state in the uterus within minutes and applies pressure (up to 90 mmHg) to induce physiologic contractions.

 

In the PEARLE study,  bleeding was controlled successfully with JADA in 94% of the participants without requiring further interventions, with a median time to control bleeding of 3 minutes.

 

Since its U.S.

 

Food and Drug Administration (FDA) approval in August 2020, JADA has been expanding its reach in Asia including Hong Kong and Singapore, as well as parts of the Middle East and South America.

 

"As the risk of postpartum hemorrhage increases in line with an increase in the mother's age, the importance of controlling postpartum hemorrhage for healthy births will continue to increase," said an Organon representative.

 

"We are working to launch JADA in Korea, but the official launch date has not been set yet." The representative added, “Organon Korea has identified a number of unmet needs in women's health and will continue to strive to provide a range of innovative medicines and solutions for various health issues that women may experience throughout their lifecycle."